Opthea Ltd
ASX:OPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Opthea Ltd
Gross Profit
Opthea Ltd
Gross Profit Peer Comparison
Opthea Ltd
Glance View
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing and commercializing therapies primarily for eye diseases. The firm's lead product candidate OPT-302, is a soluble form of vascular endothelial growth factors-3 (VEGFR 3) in clinical development as a therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The firm's technology platform focuses on vascular endothelial growth factors, such as VEGF C, VEGF D and VEGF Receptor 3 for the treatment of diseases associated with blood and lymphatic vessel growth (angiogenesis and lymphangiogenesis), as well as vascular leakage. The company has also conducted various activities to support its clinical development programs in wet AMD and DME, including clinical data analysis and manufacturing of OPT-302 for use in Phase III clinical trials.
